iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16 ,2020

Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) announced it will release its fiscal 2021 Q1 financial results on November 16, 2020, after market close. The management will host a conference call at 4:30 p.m. ET to discuss the results and provide corporate updates. Investors can access the live and archived webcast on www.ibioinc.com in the Investors section. iBio specializes in plant-based biologics manufacturing, using its patented FastPharming System to produce monoclonal antibodies, vaccines, and other proteins.

Positive

• iBio is a leader in plant-based biologics manufacturing.
• The FastPharming System enhances production efficiency of therapeutic products.

Negative

• None.

BRYAN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 first quarter financial results after market close on Monday, November 16, 2020. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (international) and entering conference code: 2546666.

About iBio, Inc.

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming^® System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBio’s Glycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, and vaccines for infectious diseases. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

When will iBio report its Q1 earnings for fiscal 2021?

iBio will report its fiscal 2021 Q1 financial results after market close on November 16, 2020.

What is the conference call number for iBio's earnings report?

The conference call number for iBio's earnings report is (833) 672-0651 for domestic calls and (929) 517-0227 for international calls.

Where can I find the live webcast for iBio's financial results?

The live webcast for iBio's financial results can be accessed at www.ibioinc.com under the News and Events section in Investors.

What technologies does iBio use in its manufacturing process?

iBio uses the FastPharming System, which combines vertical farming, automated hydroponics, and glycan engineering technologies.

What products is iBio developing?

iBio is developing proprietary products such as IBIO-100 for fibrotic diseases and vaccines for infectious diseases.